Effect of LncRNA MITA1 targeting miR-30b-3p on biological behavior of hepatocellular carcinoma cells

Abstract

Abstract: Objective To investigate the mechanistic role of LncRNA MITA1 in the progression of hepatocellular carcinoma (HCC). Methods qRT-PCR was employed to assess the expression levels of MITA1 mRNA in HCC tissues and cells. The pcDNA3.1 recombinant plasmid vector was utilized to overexpress MITA1. After treatment, SMMC7721 cells were categorized into three groups, the normal group, the OE-MITA1-NC (negative control) group, and the OE-MITA1 (overexpression) group. Cell proliferation was evaluated using a colony formation assay, while cell invasion was assessed via the Transwell assay. Cell viability was determined using the Cell Counting Kit-8 (CCK-8) assay. Protein expression levels of Vimentin, MMP-2, and N-Cadherin were measured by western blotting. Additionally, the dual-luciferase reporter assay was conducted to verify the targeting relationship between MITA1 and miR-30b-3p. Results Compared with adjacent normal liver tissues, HCC tissues and cells exhibited significantly higher expression levels of MITA1 mRNA and lower expression levels of miR-30b-3p mRNA (P<0.05). Under MITA1 overexpression conditions, the OE-MITA1 group demonstrated elevated MITA1 mRNA expression levels (P<0.05). Compared with the normal and OE-MITA1-NC groups, the OE-MITA1 group exhibited increased cell proliferation, invasion capacity, and enhanced cell viability (P<0.05). Furthermore, protein expression levels of Vimentin, MMP-2, and N-Cadherin were significantly higher in the OE-MITA1 group compared with the other two groups (P<0.05). The dual-luciferase reporter assay confirmed a targeting relationship between MITA1 and miR-30b-3p, with MITA1 expression negatively regulating miR-30b-3p expression. Conclusion LncRNA MITA1 can promotes the proliferation, invasion and cell activity of liver cancer by binding miR-30b-3p, MITA1 may serve as a potential therapeutic target for the diagnosis and treatment of HCC.

Key words: LncRNA MITA1, miR-30b-3p, hepatocellular carcinoma, proliferation, invasion

摘要： 目的探究LncRNA MITA1在肝细胞癌（HCC）发展中的作用机制。方法采用qRT-PCR检测HCC组织及细胞内MITA1 mRNA的表达;采用pcDNA3.1重组质粒载体过表达MITA1。SMMC7721细胞处理后分别标记为空白组、OE-MITA1-NC组、OE-MITA1组。平板克隆实验检测细胞增殖;Transwell检测细胞侵袭;细胞计数试剂盒-8（CCK-8）检测细胞活力;免疫印迹法检测Vimentin、MMP-2、N-Cadherin蛋白表达;双荧光素酶报告实验验证MITA1和miR-30b-3p的靶向关系。结果与癌周正常肝组织相比,HCC组织及细胞内MITA1 mRNA含量呈高表达,而miR-30b-3p mRNA呈低表达（P<0.05）;MITA1过表达下,OE-MITA1组MITA1 mRNA表达水平升高（P<0.05）。与空白组和OE-MITA1-NC组相比,OE-MITA1组细胞增殖和侵袭数量增加且细胞活性增强（P<0.05）;Vimentin、MMP-2、N-Cadherin蛋白表达升高（P<0.05）。双荧光素酶报告显示,MITA1与miR-30b-3p之间具有靶向关系,且MITA1与miR-30b-3p表达呈负调控关系。结论 LncRNA MITA1通过绑定miR-30b-3p调控并促进HCC细胞的增殖、侵袭和细胞活力,可作为HCC诊疗潜在的靶点。

关键词: 长链非编码RNA MITA1, miR-30b-3p, 肝细胞癌, 增殖, 侵袭

CLC Number:

R735.7

JIN Wen, LI Qun, WANG Bo, ZHOU Jiankun, ZHANG Jun, CAO Liyu. Effect of LncRNA MITA1 targeting miR-30b-3p on biological behavior of hepatocellular carcinoma cells[J]. Journal of Chengde Medical University, 2026, 43(1): 1-6.

金雯, 李群, 王波, 周健坤, 张俊, 曹立宇. LncRNA MITA1靶向miR-30b-3p对肝细胞癌细胞生物学活性的影响[J]. 承德医学院学报, 2026, 43(1): 1-6.

Add to citation manager EndNote|Ris|BibTeX

URL: http://tougao.cdmc.edu.cn:8088/EN/

http://tougao.cdmc.edu.cn:8088/EN/Y2026/V43/I1/1

References

[1] Anwanwan D, Singh SK, Singh S, et al.Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(1): 188314-118332.
[2] 夏永祥,张峰,李相成,等. 原发性肝癌10966例外科治疗分析[J]. 中华外科杂志,2021,59(1):6-17.
[3] Mortezaee K, Majidpoor J, Kharazinejad E.Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated[J]. Med Oncol, 2022, 39(12): 193.
[4] 孙健,俞建康,段妍西,等. 长链非编码RNA OIP5-AS1促进结直肠癌细胞上皮-间质转化[J]. 中国医科大学学报,2024,53(10):877-880.
[5] Yao ZT, Yang YM, Sun MM, et al.New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer[J]. Cancer Commun (Lond), 2022, 42(2): 117-140.
[6] Guo X, Wang Y, Zheng D, et al.LncRNA-MIAT promotes neural cell autophagy and apoptosis in ischemic stroke by up-regulating REDD1[J]. Brain Res, 2021, 1763: 147436.
[7] Hu J, Dong SW, Pei Y, et al.LncRNA MITA1 promotes gefitinib resistance by inducing autophagy in lung cancer cells[J]. Biochem Biophys Res Commun, 2021, 551: 21-26.
[8] Ma M, Xu H, Liu G, et al.Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis[J]. Hepatology, 2019, 70(1): 215-230.
[9] Li Y, Ma X, Li J, et al.LncRNA gas5 regulates granulosa cell apoptosis and viability following radiation by X-ray through sponging miR-205-5p and Wnt/β-catenin signaling pathway ingranulosa cell tumor of ovary[J]. Trop JPharm Res, 2021, 19(12): 2491-2498.
[10] 吴涛,杨柳,聂山茂,等. 长链非编码RNA SNHG16通过miR-141-3p/FOXJ3通路调控肝细胞癌的增殖[J]. 承德医学院学报,2022,39(4):271-276.
[11] Li YH, Xi X, Zhang M, et al.High expression of LINC00467 promotes proliferation and metastasis of lung adenocarcinoma cells by suppressing autophagy via inhibiting the AMPK/mTOR pathway[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2024, 44(10): 1898-1909.
[12] Chen YY, Shen H, Liu TT, et al.ATR-binding IncRNA ScaRNA2 promotes cancer resistance through facilitating efficient DNA end resection during homologous recombination repair[J]. J Exp Clin Cancer Res, 2023, 42(1): 256-278.
[13] Hou JY, Long HB, Zhou CQ, et al.Long noncoding RNA Braveheart promotes cardiogenic differentiation of mesenchymal stem cells in vitro[J]. Stem Cell Res Ther, 2017, 8(1): 4-17.
[14] Zhou CF, Yi CH, Yi YX, et al.LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes[J]. Mol Cancer, 2020, 19(1): 118-142.
[15] Li Y, Zhou JH, Wang J, et al.Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene[J]. Biol Res, 2020, 53(1): 10-18.
[16] 陈琳,陈新璐,刘璐,等. miR-30b-3p通过靶向调控COX6B1抑制肺腺癌细胞的增殖和侵袭[J]. 中国肺癌杂志,2022,25(8):567-574.
[17] Croset M, Pantano F, Kan CWS, et al.miRNA30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasisassociated genes[J]. Cancer Res, 2018, 78(18): 52595273.